Eris Lifesciences Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Amit Bakshi
Chief executive officer
₹48.8m
Total compensation
| CEO salary percentage | 35.9% |
| CEO tenure | 17.3yrs |
| CEO ownership | 42.9% |
| Management average tenure | 7.6yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Investor Optimism Abounds Eris Lifesciences Limited (NSE:ERIS) But Growth Is Lacking
Aug 22Eris Lifesciences Limited (NSE:ERIS) Looks Interesting, And It's About To Pay A Dividend
Aug 08Should You Buy Eris Lifesciences Limited (NSE:ERIS) For Its Upcoming Dividend?
Aug 08Eris Lifesciences Limited's (NSE:ERIS) Risks Elevated At These Prices
Jul 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹4b |
| Sep 30 2023 | n/a | n/a | ₹4b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹49m | ₹17m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹46m | ₹26m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹4b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹27m | ₹27m | ₹4b |
| Dec 31 2020 | n/a | n/a | ₹3b |
| Sep 30 2020 | n/a | n/a | ₹3b |
| Jun 30 2020 | n/a | n/a | ₹3b |
| Mar 31 2020 | ₹49m | ₹18m | ₹3b |
| Dec 31 2019 | n/a | n/a | ₹3b |
| Sep 30 2019 | n/a | n/a | ₹3b |
| Jun 30 2019 | n/a | n/a | ₹3b |
| Mar 31 2019 | ₹49m | ₹18m | ₹3b |
| Dec 31 2018 | n/a | n/a | ₹3b |
| Sep 30 2018 | n/a | n/a | ₹3b |
| Jun 30 2018 | n/a | n/a | ₹3b |
| Mar 31 2018 | ₹49m | ₹11m | ₹3b |
Compensation vs Market: Amit's total compensation ($USD584.73K) is above average for companies of similar size in the Indian market ($USD420.57K).
Compensation vs Earnings: Amit's compensation has been consistent with company performance over the past year.
CEO
Amit Bakshi (47 yo)
17.3yrs
Tenure
₹48,776,648
Compensation
Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | no data | ₹48.78m | 42.88% ₹ 52.3b | |
| President | no data | ₹12.31m | no data | |
| Chief Financial Officer | 7.6yrs | ₹14.35m | no data | |
| Executive Director & COO | 2.9yrs | ₹44.85m | no data | |
| Compliance Officer & Company Secretary | 7.6yrs | no data | no data | |
| President of Sales & Marketing | no data | ₹11.24m | no data | |
| Executive Director | no data | ₹12.40m | 4.37% ₹ 5.3b | |
| Whole Time Director | no data | ₹6.99m | 3.28% ₹ 4.0b | |
| Senior Vice President | no data | ₹12.64m | no data | |
| Vice President | no data | ₹13.30m | no data | |
| Vice President | no data | ₹10.67m | no data | |
| Vice President | no data | ₹13.12m | no data |
7.6yrs
Average Tenure
49.5yo
Average Age
Experienced Management: ERIS's management team is seasoned and experienced (7.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 17.3yrs | ₹48.78m | 42.88% ₹ 52.3b | |
| Executive Director & COO | 3.3yrs | ₹44.85m | no data | |
| Executive Director | 17.3yrs | ₹12.40m | 4.37% ₹ 5.3b | |
| Whole Time Director | 3.7yrs | ₹6.99m | 3.28% ₹ 4.0b | |
| Independent Director | 6yrs | ₹3.98m | no data | |
| Independent Director | 1.8yrs | ₹2.82m | no data | |
| Independent Director | 3.3yrs | ₹4.53m | no data | |
| Independent Director | 3.3yrs | ₹4.20m | no data |
3.5yrs
Average Tenure
49yo
Average Age
Experienced Board: ERIS's board of directors are considered experienced (3.5 years average tenure).